U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the ...

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

Feb 4 (Reuters) - Biotech firm PrimeGen US will go public in the United States through a $1.5 billion deal with blank-check ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

Eikon Therapeutics increased the size of its initial public offering at the last minute and priced at the top of its range, ...

However, there are certain things AI can't do -- and may never be able to do. One of them is to cure diseases. Biotech companies that develop and market breakthrough therapies for, thus far, ...

Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New ...